Canon debuts Alphenix version for labs and centers
Canon Medical Systems USA has introduced Alphenix Aero Edition, a new interventional...Read more on AuntMinnie.comRelated Reading: Canon plans to open Middle East division Canon unveils Alphenix Encore Plus Program Canon's CT portfolio primed for lung cancer screening Canon installs 3T MRI scanner in Colo. Canon makes 1st Alphenix Core+ install in Fla.
Conclusions: Despite low accrual, majority of subjects treated with metformin had metabolic responses by PERCIST criteria on PET imaging. Contrary to the effect of metformin on most physiologic tissues, most tumors had increased metabolic activity in response to metformin.
ConclusionPET/CT-based signature can be used prior to initiation of immunotherapy to identify NSCLC patients most likely to benefit from immunotherapy. As such, these data may be leveraged to improve more precise and individualized decision support in the treatment of patients with advanced NSCLC.
AbstractBackgroundMetabolic information obtained through18F-flurodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is used to evaluate malignancy by calculating the glucose uptake rate, and these parameters play important roles in determining the prognosis of non-small cell lung cancer (NSCLC). The expression of immune-related markers in tumor tissue reflects the immune status in the tumor microenvironment. However, there is lack of reports on the association between metabolic variables and intra-tumor immune markers. Herein, we investigate the correlation between metabolic status on18F-FDG PET...
AbstractPurposePrimary tumor (PT) and metastatic lymph node (MLN) status have a great influence on diagnosis and treatment of lung cancer. Our main purpose was to investigate the imaging characteristics of PT or MLN by applying the18F-FDG PET dynamic modeling approach for non-small cell lung cancer (NSCLC).MethodsDynamic18F-FDG PET scans were performed for 76 lung cancer patients, and 62 NSCLC cases were finally included in this study: 37 with newly diagnosed early and locally advanced lung cancer without distant metastases (group M0) and 25 metastatic lung cancer (group M1). Patlak graphic analysis (Ki calculation) based ...
Authors: Ruppert AM, Lavolé A, Makinson A, Le Maître B, Cadranel J Abstract Lung cancer is the leading cause of cancer related death among people living with HIV (PLHIV). Tobacco exposure is higher among PLHIV (38.5%) and mainly explains the increased risk of lung cancer. To reduce lung cancer mortality, two approaches need to be implemented: lung cancer screening with low-dose thoracic CT scan and smoking cessation. Low dose CT scan is feasible in PLHIV. The false positive rate is not higher than in the general population, except for cases with CD4
Authors: Filice A, Casali M, Ciammella P, Galaverni M, Fioroni F, Lotti C, Versari A Abstract The goal of the radiotherapy (RT) planning process is to select and delineate target volumes with the best accuracy on the basis of all the available diagnostic information and the knowledge of the physiology of the disease. The recommendation of the International Atomic Energy Agency (IAEA) expert panel, is that an appropriately timed and technically adequate 2-[18F]fluoro-2-deoxy-d-glucose/Positron Emission Tomography-Computer Tomography (18F-FDG-PET/CT) imaging is an essential component in the radiotherapy treatment pla...
(American Association for Cancer Research) Using standard-of-care computed tomography (CT) scans in patients with advanced non-small cell lung cancer (NSCLC), researchers utilized artificial intelligence (AI) to train algorithms to predict tumor sensitivity to three systemic cancer therapies.
Blacks and Hispanics are less likely to undergo guideline-recommended PET and CT scans at diagnosis of non-small-cell lung cancer (NSCLC), according to a database study.Reuters Health Information
CONCLUSION: The prediction model that incorporates the radiomics signature and clinical risk factors has potential to facilitate the individualized prediction of PD-L1 expression in NSCLC patients and identify patients who can benefit from anti-PD-L1 immunotherapy. PMID: 32176676 [PubMed - as supplied by publisher]
This study is a multicenter, prospective, single ‐arm, phase II clinical study, and explores the efficacy and tolerability of SRS with anlotinib in NSCLC patients with limited brain metastases. The aim of the study is to provide new treatment options for NSCLC patients with brain metastases.